Neurology Archives - BlueRock Therapeutics LP

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

Designation enables preferred procedural treatment and review consultation by Japan’s Ministry of Health, Labor and Welfare Parkinson’s disease affects approximately 10 million people worldwide and 250,000 in Japan Berlin, Germany and Cambridge, MA, USA, December 17, 2025 – Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy […]

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary clinical efficacy endpoints related to motor outcomes remain stable compared to 24 months and continue to show positive trends from baseline Data were presented […]

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel

BlueRock announced that the first patient has received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for Parkinson’s disease.

Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses

Mucopolysaccharidoses are inherited metabolic disorders caused by the deficiency in lysosomal enzymes required to break down glycosaminoglycans. Accumulation of glycosaminoglycans leads to progressive, systemic degenerative disease. The central nervous system is particularly affected, resulting in developmental delays, neurological regression, and early mortality. Current treatments […]

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Regenerative Medicine Advanced Therapy (RMAT) designation follows phase I clinical trial results demonstrating that bemdaneprocel is well tolerated with no major safety issues through 18 months Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s […]

Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in […]

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months After stopping the 12-month immune suppression regimen, assessment of 18-month data shows evidence of sustained cell engraftment […]

Headlines of the Future Podcast: The Future of Cell and Gene Therapies

Parkinson’s Disease is a relentless adversary for the human body, and over 10 million people worldwide fight a daily battle against it. Despite more than 65 years of research, current therapies sill only provide symptomatic relief. Join us as our expert panel discusses why Parkinson’s […]

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

This press release was updated on October 2, 2023. Specifically, two data points have been updated after it was discovered that the data point from the Hauser diary OFF time in the low dose cohort and the data point from the MDS-UPDRS Part III low […]

BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study

Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment Phase II clinical study expected to begin enrolling patients in H1 […]